Percheron Therapeutics (ASX:PER) Long-Term Capital Lease Obligation : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics Long-Term Capital Lease Obligation?

Percheron Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Percheron Therapeutics's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.05 Mil) but then declined from Jun. 2023 (A$0.05 Mil) to Dec. 2023 (A$0.00 Mil).

Percheron Therapeutics's annual Long-Term Capital Lease Obligation declined from Jun. 2021 (A$0.23 Mil) to Jun. 2022 (A$0.13 Mil) and declined from Jun. 2022 (A$0.13 Mil) to Jun. 2023 (A$0.05 Mil).

Percheron Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Percheron Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Long-Term Capital Lease Obligation Chart

Percheron Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.02

0.23

0.13

0.05

Percheron Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	0.13	-	0.05	-

Percheron Therapeutics (ASX:PER) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Percheron Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Percheron Therapeutics (ASX:PER) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ATHJF:USA AWY0:Germany

Address

14 Wallace Avenue, Toorak, VIC, AUS, 3142

Website

https://www.antisense.com.au

Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.

Percheron Therapeutics (ASX:PER) Headlines

No Headlines